-
公开(公告)号：US20230241103A1
公开(公告)日：2023-08-03
申请号：US17820724
申请日：2022-08-18
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , C07K16/28 , A61P35/02 , A61K39/395 , A61K48/00
CPC分类号： A61K35/17 , C07K14/7051 , C07K14/70517 , C07K16/2803 , A61P35/02 , A61K39/39558 , A61K48/0016 , A61K2039/505
摘要： Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US11236171B2
公开(公告)日：2022-02-01
申请号：US16471485
申请日：2017-12-21
IPC分类号： C07K16/28 , A61K39/395 , G01N33/53 , A61K47/69 , A61K47/68 , A61P35/02 , A61P35/04 , A61P35/00 , C07K14/725 , C07K14/705 , C07K16/46 , G01N33/577
摘要： Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
-
公开(公告)号：US11066479B2
公开(公告)日：2021-07-20
申请号：US16322712
申请日：2017-07-20
发明人： Mitchell Ho , Nan Li , Dimiter S. Dimitrov
摘要： A panel of human variable heavy (VH) single domain monoclonal antibodies specific for cell-surface glypican-2 (GPC2) are described. Methods for the diagnosis and treatment and GPC2-positive cancer are also described. Recombinant immunotoxins comprised of a GPC2-specific VH domain antibody and a clinically used form of Pseudomonas exotoxin A (PE38) were generated and shown to inhibit GPC2-positive neuroblastoma tumor cell growth and inhibit neuroblastoma xenograft growth in nude mice, without significant toxicity. Chimeric antigen receptors comprising a GPC2-specific VH single domain antibody are also described. T cells expressing the GPC2-specific CARs potently killed GPC2-positive neuroblastoma cells in a dose-dependent manner.
-
公开(公告)号：US20190218280A1
公开(公告)日：2019-07-18
申请号：US16252158
申请日：2019-01-18
申请人： Lentigen Technology Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/18 , C07K14/705 , C07K16/30 , C07K14/725 , A61P35/02 , A61P35/00 , A61K35/17
摘要： Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20190106492A1
公开(公告)日：2019-04-11
申请号：US16132064
申请日：2018-09-14
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/28 , C12N5/0783 , A61P35/00 , C07K14/705 , C07K14/725 , A61K35/17
摘要： Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20190099476A1
公开(公告)日：2019-04-04
申请号：US16161542
申请日：2018-10-16
申请人： LentigenTechnology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K39/00 , C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00
摘要： Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
-
公开(公告)号：US20180208645A1
公开(公告)日：2018-07-26
申请号：US15866222
申请日：2018-01-09
申请人： Lentigen Technology Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/18 , A61K35/17 , A61P35/00 , C07K14/705 , C07K14/725 , A61P35/02
CPC分类号： C07K16/18 , A61K35/17 , A61P35/00 , A61P35/02 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/30 , C07K2317/21 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/33
摘要： Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20160208015A1
公开(公告)日：2016-07-21
申请号：US15090873
申请日：2016-04-05
发明人： Mitchell Ho , Mingqian Feng , Dimiter S. Dimitrov
IPC分类号： C07K16/30 , C07K14/21 , G01N33/574 , C07K16/28
CPC分类号： C07K16/3076 , A61K39/39558 , A61K47/6803 , A61K47/6813 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K14/21 , C07K16/28 , C07K16/303 , C07K16/3092 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00 , C07K2319/33 , C07K2319/55 , G01N33/57438 , G01N33/57492 , G01N33/6893 , G01N2333/705 , G01N2400/40
摘要： Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.
-
公开(公告)号：US20240309102A1
公开(公告)日：2024-09-19
申请号：US18733957
申请日：2024-06-05
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/28 , A61K35/17 , A61K38/00 , C07K14/705 , C07K14/725 , C12N15/10 , C12N15/86
CPC分类号： C07K16/2866 , A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C12N15/1037 , C12N15/86 , A61K38/00 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2740/15041
摘要： Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US12037403B2
公开(公告)日：2024-07-16
申请号：US17095982
申请日：2020-11-12
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K39/00 , A61K35/17 , A61K39/395 , C07K14/47 , C07K14/705 , C07K14/725 , C07K16/28 , C07K19/00 , C12N15/10 , C12N15/86 , A61K38/00
CPC分类号： C07K16/2866 , A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C12N15/1037 , C12N15/86 , A61K38/00 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2740/15041
摘要： Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.045 秒)
